Asclepius Meditec

Founded in 2011, Asclepius Meditec is the first company in the world to conduct clinical research on hydrogen and oxygen. The company has made significant advancements in the field of medical-grade hydrogen oxygen ventilators, aiming to improve natural breathing for patients. With a strong focus on Health Care and Medical Devices, Asclepius Meditec has conducted nearly 200 basic studies, 18 single-center clinical studies, 6 multi-center clinical studies, and 7 national natural fund projects. They have also published 46 SCI papers and monograph books on "Hydrogen Control Cancer." Moreover, Asclepius Meditec has been instrumental in analyzing the effects of its hydrogen and oxygen ventilator on COVID-19 patients. The data from nearly 300 cases revealed significant improvements in shortness of breath, chest distress, chest pain, respiratory frequency, heart rate, and oxygen saturation after inhaling the mixed gas of hydrogen and oxygen. Overall, Asclepius Meditec presents an innovative approach to medical treatment and holds promise for enhancing respiratory care. Given its research-backed solutions and pioneering position in the industry, it may attract interest from venture capital firms seeking impactful healthcare and medical device investments.